ALDE – Alder BioPharmaceuticals, Inc.

Latest News & Stock Analysis

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine and other underserved conditions. The company’s business model revolves around the discovery, development, and commercialization of innovative therapies that address significant unmet medical needs. Alder’s lead product candidate, eptinezumab, is an investigational monoclonal antibody (mAb) designed for migraine prevention. The innovative aspect of Alder’s approach lies in its focus on targeting calcitonin gene-related peptide (CGRP), a key neuropeptide associated with migraine, and its development of a quarterly administered infusion therapy. Investors interested in stocks and investment opportunities in the biopharmaceutical sector may find news on ALDE and analysis of ALDE relevant to understanding market trends in migraine treatment and antibody therapeutics.

Aldebaran and Rio Tinto. A Strategic Alliance?
ALDE

Aldebaran and Rio Tinto. A Strategic Alliance?

by | 22/03/2025 10:00 PM | ALDE

🤝 Aldebaran has a significant agreement with Nuton, a subsidiary of Rio Tinto, which is making substantial investments that could lead to acquiring 20% of the company.

⛰️ The Altar deposit is the fifth-largest copper deposit held by a junior mining company, with 2.4 billion tons of copper at 0.42%.

📈 The company is conducting studies for the PEA in 2025 and plans the PCS for the last quarter of 2026, with strong management led by John Black.

Read more!